Tagrisso Tablets: Product Details
Tagrisso is a prescription oncology medicine containing osimertinib, a targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is designed for patients whose cancer has specific epidermal growth factor receptor (EGFR) mutations, as determined by appropriate diagnostic testing. Treatment selection and monitoring must be managed by a qualified oncology specialist.
For pharmaceutical distributors, procurement teams, hospitals, and authorized healthcare suppliers in the United States, accurate product identification and regulatory documentation are essential when sourcing oncology medicines.
Cordium Pharmaceuticals Pvt. Ltd., based in India, is a supplier and exporter of oncology medicines. Businesses interested in Tagrisso product information can contact Cordium Pharma to discuss product specifications, documentation requirements, and potential supply enquiries, subject to availability and applicable regulations.
Tagrisso Tablet Strengths and Specifications
Tagrisso tablets are listed in two strengths in US prescribing information:
Tagrisso 40 mg tablets: An available tablet strength containing 40 mg of osimertinib.
Tagrisso 80 mg tablets: An available tablet strength containing 80 mg of osimertinib.
Both strengths are prescription-only products. The appropriate dose depends on the patient's diagnosis, treatment setting, response, and tolerability. Patients should not change their dose without medical guidance.
For verified product specifications, refer to the official DailyMed Tagrisso prescribing information.
Uses and Important Safety Information
Osimertinib is used for specific EGFR-mutated NSCLC indications. Eligibility depends on the cancer's molecular characteristics and the applicable treatment indication.
Potential adverse effects include diarrhoea, skin reactions, nail changes, fatigue, and reduced blood-cell counts. Serious risks can include interstitial lung disease or pneumonitis, heart rhythm abnormalities, and cardiac complications. Medical supervision and appropriate monitoring are essential.
Tagrisso should be used only under the direction of an authorized healthcare professional. This article provides general product information and does not replace the official prescribing information or individualized medical advice.
Oncology Medicine Supply from India
Cordium Pharmaceuticals Pvt. Ltd. welcomes enquiries from qualified pharmaceutical buyers, distributors, and healthcare procurement organizations seeking oncology product information.
Before initiating a purchase enquiry, buyers should confirm the required strength, product presentation, manufacturer details, batch documentation, storage conditions, and destination-country requirements. Importing prescription medicines into the United States is subject to FDA requirements, including applicable drug approval, establishment registration, listing, labeling, and manufacturing standards. Foreign supply alone does not establish that a product is authorized for US marketing.
Contact Cordium Pharma to discuss relevant product documentation and potential supply arrangements. All transactions must comply with applicable laws and regulatory requirements.
Frequently Asked Questions
1. What is Tagrisso used for?
Tagrisso contains osimertinib, a targeted prescription medicine used for certain types of EGFR-mutated non-small cell lung cancer.
2. What strengths of Tagrisso tablets are available?
The US prescribing information lists 40 mg and 80 mg tablets. Confirm the exact product presentation and availability with the supplier.
3. Can I purchase Tagrisso tablets without a prescription?
No. Tagrisso is a prescription medicine and requires appropriate medical oversight.
4. Does Cordium Pharmaceuticals export oncology medicines from India?
Cordium Pharmaceuticals Pvt. Ltd. identifies itself as an India-based oncology medicine supplier and exporter. Contact the company directly to verify product-specific availability, documentation, and eligible destinations.
5. Can Tagrisso be imported into the USA from India?
Importation depends on the product's regulatory status and applicable US law. Buyers should verify FDA requirements before placing an order; not every foreign-sourced version is eligible for US importation.
6. How can buyers enquire about Tagrisso?
Qualified buyers can contact Cordium Pharmaceuticals Pvt. Ltd. with their required strength, intended market, documentation needs, and procurement details for review.
Disclaimer: This content is for general informational and business procurement purposes only. It does not constitute medical advice, establish product availability, or guarantee regulatory approval in the United States.
Tagrisso is a prescription oncology medicine containing osimertinib, a targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is designed for patients whose cancer has specific epidermal growth factor receptor (EGFR) mutations, as determined by appropriate diagnostic testing. Treatment selection and monitoring must be managed by a qualified oncology specialist.
For pharmaceutical distributors, procurement teams, hospitals, and authorized healthcare suppliers in the United States, accurate product identification and regulatory documentation are essential when sourcing oncology medicines.
Cordium Pharmaceuticals Pvt. Ltd., based in India, is a supplier and exporter of oncology medicines. Businesses interested in Tagrisso product information can contact Cordium Pharma to discuss product specifications, documentation requirements, and potential supply enquiries, subject to availability and applicable regulations.
Tagrisso Tablet Strengths and Specifications
Tagrisso tablets are listed in two strengths in US prescribing information:
Tagrisso 40 mg tablets: An available tablet strength containing 40 mg of osimertinib.
Tagrisso 80 mg tablets: An available tablet strength containing 80 mg of osimertinib.
Both strengths are prescription-only products. The appropriate dose depends on the patient's diagnosis, treatment setting, response, and tolerability. Patients should not change their dose without medical guidance.
For verified product specifications, refer to the official DailyMed Tagrisso prescribing information.
Uses and Important Safety Information
Osimertinib is used for specific EGFR-mutated NSCLC indications. Eligibility depends on the cancer's molecular characteristics and the applicable treatment indication.
Potential adverse effects include diarrhoea, skin reactions, nail changes, fatigue, and reduced blood-cell counts. Serious risks can include interstitial lung disease or pneumonitis, heart rhythm abnormalities, and cardiac complications. Medical supervision and appropriate monitoring are essential.
Tagrisso should be used only under the direction of an authorized healthcare professional. This article provides general product information and does not replace the official prescribing information or individualized medical advice.
Oncology Medicine Supply from India
Cordium Pharmaceuticals Pvt. Ltd. welcomes enquiries from qualified pharmaceutical buyers, distributors, and healthcare procurement organizations seeking oncology product information.
Before initiating a purchase enquiry, buyers should confirm the required strength, product presentation, manufacturer details, batch documentation, storage conditions, and destination-country requirements. Importing prescription medicines into the United States is subject to FDA requirements, including applicable drug approval, establishment registration, listing, labeling, and manufacturing standards. Foreign supply alone does not establish that a product is authorized for US marketing.
Contact Cordium Pharma to discuss relevant product documentation and potential supply arrangements. All transactions must comply with applicable laws and regulatory requirements.
Frequently Asked Questions
1. What is Tagrisso used for?
Tagrisso contains osimertinib, a targeted prescription medicine used for certain types of EGFR-mutated non-small cell lung cancer.
2. What strengths of Tagrisso tablets are available?
The US prescribing information lists 40 mg and 80 mg tablets. Confirm the exact product presentation and availability with the supplier.
3. Can I purchase Tagrisso tablets without a prescription?
No. Tagrisso is a prescription medicine and requires appropriate medical oversight.
4. Does Cordium Pharmaceuticals export oncology medicines from India?
Cordium Pharmaceuticals Pvt. Ltd. identifies itself as an India-based oncology medicine supplier and exporter. Contact the company directly to verify product-specific availability, documentation, and eligible destinations.
5. Can Tagrisso be imported into the USA from India?
Importation depends on the product's regulatory status and applicable US law. Buyers should verify FDA requirements before placing an order; not every foreign-sourced version is eligible for US importation.
6. How can buyers enquire about Tagrisso?
Qualified buyers can contact Cordium Pharmaceuticals Pvt. Ltd. with their required strength, intended market, documentation needs, and procurement details for review.
Disclaimer: This content is for general informational and business procurement purposes only. It does not constitute medical advice, establish product availability, or guarantee regulatory approval in the United States.
Keywords
